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ABSTRACT 
The present study is to develop and evaluate an ethosomal gel formulation of acyclovir (ACV). It aims to provide a topical treatment for many 
viral infections that affect the skin. Administration of medications topically having the facility of delivering a high concentration of the drug to 
the skin than would be possible with systemic therapy. Topical administration of drugs is better for local action and the efficiency of the 
topically administered drug is increased with liposome, proliposomes and ethosomes. Recently, it was found that ethosomal carriers were 
phospholipid vesicular systems having relatively high concentrations of alcohol, enhances dermal and transdermal delivery of both lipophilic as 
well as hydrophilic molecules. ACV is the common antiviral agent that is used to treat infections caused by certain types of viruses. It treats cold 
sores around the mouth (caused by herpes simplex), shingles (caused by herpes zoster) and chickenpox. ACV 5% cream is used for the treatment of 
infection along with oral dosage forms like tablets. These formulations show poor therapeutic outcome due to the poor bioavailability (15-20%) 
of oral dosage forms. Ethosomes were formulated using phospholipid, ethanol, polyethylene glycol and purified water by cold method. 
Ethosomes were evaluated for vesicle size, shape, optical microscopy, entrapment efficiency and in-vitro release study. AEF5 have better drug 
entrapment efficiency than the other formulation. The best formulation (AEF5) was used to prepare gel by using carbopol 934 as a gelling 
agent. The ethosomes were entrapped in gel matrix of carbopol 980 in different concentration 0.5%, 1.00% and 1.5% w/w. FT -IR studies 
revealed no interaction between the drug and excipients. The formulated gel formulation was evaluated with parameter pH, viscosity, 
spreadability, in-vitro release test, washability, extrudability study and stability studies. The formulation AEG2 have better in-vitro drug release 
profile which contains carbopol 980 concentration 1%w/w. The present work also focuses on making the formulation more pharmaceutically 
acceptable.  
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INTRODUCTION 
In the past decades, topical delivery of drug by liposomal 
formulation have evoked considerable interest, it has been 
evident that traditional; liposomes are of little or no value as 
carrier for transdermal delivery of drug, because they do not 
deeply penetrate skin but remains confined to upper layer of 
the stratum corneum. To overcome problem of poor skin 
permeability Cave et al and Touitou et al recently introduce 
two new vesicular system transferosomes and ethosomes 
incorporated edge activator (surfactant) and penetration 
enhancer (alcohols and polyols) respectively to influence the 
properties of vesicles and stratum corneum1-3. Ethosomes 
are soft malleable vesicles composed mainly of phospholipid, 
ethanol (relatively high concentration) and water. These soft 
vesicles represents novel vesicular carrier for enhanced 
delivery to/through skin. The size of ethosome vesicles can 
be modulated from tens of microns to nanometres. This 
carrier presents interesting features correlated with its 
ability to permeate intact through the human skin due to its 
high deformability4. The high concentration of ethanol 
makes the ethosome unique, as ethanol is known for, its 
disturbance of lipid bilayer organization; therefore when 
integrated into a vesicle membrane, it gives that vesicle the 
ability to penetrate the stratum corneum. Also because of 
their high ethanol concentration, lipid membrane is packed 
less tightly than conventional vesicles, but has equivalent 
stability allowing a more malleable structure and improves 
drug distribution ability in stratum corneum lipid. As 
compared to classical liposomes that delivered drug to outer 
layers of skin, ethosomes were shown to enhance 
permeation through the stratum corneum barrier5. Horwtiz 
et al in a two armed, double blind, randomized clinical study, 
compared the efficacy of 5% ACV in a novel liposomal 
carrier (ethosomes) was compared to that of a commercial 
5% ACV cream (Zovirax Cream) and reported that a 5% ACV 
ethosomal preparation showed significant improvement in 
treatment of herpetic infection 6. Dayan et al investigated the 
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delivery of trihexyphenidyl HCl (THP) from ethosomes 
versus classic liposomes and concluded that in comparison 
to standard liposomes, ethosomes had higher entrapment 
efficacy and a greater ability to deliver entrapped 
fluorescent probe to the deeper layer of skin. The flux of THP 
through nude mouse skin from THP ethosomes was higher 
than liposomes7. Similarly Lodzki et al. designed a 
transdermal delivery system for cannabidiol by using 
ethosomal carrier, concluded that transdermal application of 
ethosomal cannabidiol prevented the inflammation and 
edema induced by sub plantar injection of carrageenan in 
the same animal model. Thus ethosomes enabled 
cannabidiol skin permeation and its accumulation in a depot 
at level that demonstrated8. Touitou et al prepared 
ethosomal drug delivery system of testosterone and 
minoxidil and studied the depth of skin permeation and 
demonstrated that the ethosomes enhanced the delivery of 
drug to skin in terms of both depth and quantity of skin 
permeation of testosterone and minoxidil9. Therefore, 
reliable drug delivery systems providing better drug 
penetration can result in better efficacy and also help in the 
prevention of development of resistance. The aim of the 
present study was to statistically optimize the ethosomal gel 
for enhanced skin delivery of ACV which was effective 
candidate for the treatment of viral infection. 
MATERIALS AND METHODS 
Material 
Acyclovir was obtained as a gift sample from Macleods 
Pharmaceuticals, Mumbai. Phospholipid was purchased 
from Himedia Laboratory, Mumbai. Ethanol, propylene 
glycol and carbopol-934 purchased from CDH chemical Pvt. 
Ltd. New Delhi. Dialysis membrane of Mol Wt cutoff 1200 
was purchased from Himedia Laboratory, Mumbai. Double 
distilled water was prepared freshly and used whenever 
required. All other ingredients and chemicals used were of 
analytical grade. 
Determination of λ max of ACV 
Accurately weighed 10 mg of drug was dissolved in 10 ml of 
7.4 pH buffer solution in 10 ml of volumetric flask. The 
resulted solution 1000µg/ml and from this solution 1 ml 
pipette out and transfer into 10 ml volumetric flask and 
volume make up with 7.4 pH buffer solution prepare 
suitable dilution to make it to a concentration range of 5-
25μg/ml. The spectrum of this solution was run in 200-400 
nm range in U.V. spectrophotometer (Labindia-3000+). A 
graph of concentration Vs absorbance was plotted. 
Preparation of ACV ethosomes 
Ethosomal formulations were prepared by using the cold 
method. This is the most common and widely used method 
for the ethosomal preparation. Phospholipid and drug and 
other pharmaceutical ingredient listed in table were 
dissolved in ethanol in a covered vessel at room temperature 
with vigorous stirring. This mixture was heated to 300 C ± 
10C and a fine stream of distilled water was added slowly, 
with constant mixing at 700 rpm with a mechanical stirrer in 
a closed container. Mixing was continued for an additional 5 
minutes, while maintaining the system at 300C ± 10C. The 
preparation was left to cool at room temperature for 30 min 
and then it was sonicated at 40 C for five cycles of 3 minutes 
each with a minute rest between cycles using a probe 
sonicator9. Six ethosomal formulae were presented in Table 
1.
   
Table 1 Different composition of ethosomes formulation 
F. Code Drug  
(mg) 
Phospholipid 
(mg) 
Ethanol 
(ml) 
PEG 
(mg) 
Water 
(ml) 
AEF1 500 250 5 20 10 
AEF2 500 500 5 20 10 
AEF3 500 750 5 20 10 
AEF4 500 250 10 20 10 
AEF5 500 500 10 20 10 
AEF6 500 750 10 20 10 
 
Evaluation of ACV loaded ethosomes  
Microscopic observation of prepared ethosomes  
An optical microscope (cippon, Japan) with a camera 
attachment (Minolta) was used to observe the shape of the 
prepared ethosomes formulation.  
Surface charge and vesicle size 
The vesicles size and size distribution and surface charge 
were determined by Dynamic Light Scattering method (DLS) 
(Malvern Zetamaster, ZEM 5002, Malvern, UK). 
Zeta potential 
The zeta potential was calculated according to Helmholtz–
Smoluchowsky from their electrophoretic mobility. For 
measurement of zeta potential, a zetasizer was used with 
field strength of 20 V/cm on a large bore measures cell. 
Samples were diluted with 0.9% NaCl adjusted to a 
conductivity of 50 lS/cm. 
 
 
Entrapment efficiency 
Entrapment efficiency was determined by measuring the 
concentration of unentrapped free drug in aqueous medium. 
About 1 ml of the drug loaded ethosomes dispersion was 
placed in the Ependorf tubes and centrifuged at 17000 rpm 
for 30 min. The ethosomes along with encapsulated drug 
were separated at the bottom of the tubes. Plain ethosomes 
without drug was used as blank sample and centrifuged in 
the same manner. In order to measure the free drug 
concentration, the UV absorbance of the supernatant was 
determined at 242 nm. 
Preparation of ethosomal gels 
The incorporation of the acyclovir loaded ethosomes 
(equivalent to 5%) into separate 10gm gels was achieved by 
slow mechanical mixing at 25 rpm for 10 minutes. The 
optimized formulation was incorporated into three different 
carbapol gel concentration 0.5, 1 and 1.5% w/w. The 
composition of acyclovir gel formulation was given in table 
2. 
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2 Different composition of ACV gel formulation 
S. No.  F. Code Carbopol gel 
1. AEG1 0.5% 
2. AEG2 1% 
3. AEG3 1.5% 
 
Evaluation of gel  
Physical characteristic  
The Physical Characteristic was checked for gel 
formulations (homogeneity and texture). 
Determination of pH  
The pH of the gels was determined by digital pH meter. One 
gram of gel was dissolved in 25 ml of distilled water and the 
electrode was then dipped in to gel formulation for 30 min 
until constant reading obtained.  And constant reading was 
noted. The measurements of pH of each formulation were 
replicated two times. 
Washability 
Formulations were applied on the skin and then ease and 
extent of washing with water were checked manually. 
Extrudability study  
The gel formulations were filled into collapsible metal tubes 
or aluminium collapsible tubes. The tubes were pressed to 
extrude the material and the extrudability of the formulation 
was checked.  
Spreadability  
An important criterion for gels is that it must possess good 
spreadability. Spreadability is a term expressed to denote 
the extent of area to which the gel readily spreads on 
application to skin. The therapeutic efficacy of a formulation 
also depends on its spreading value. A special apparatus has 
been designed to study the spreadability of the formulations. 
Spreadability is expressed in terms of time in seconds taken 
by two slides to slip off from formulation, placed between, 
under the application of a certain load. Lesser the time taken 
for the separation of two slides, better the spreadability.  It is 
determine by formula given below. 
  
   
 
 
Where, S=Spreadability (gcm/sec), m = weight tied to the 
upper slide (20 grams),  
l= length of glass slide (6cms), t = time taken is seconds. 
Viscosity  
The measurement of viscosity of the prepared gel was done 
using Brookfield digital Viscometer. The viscosity was 
measured using spindle no. 6 at 10 rpm and 250C. The 
sufficient quantity of gel was filled in appropriate wide 
mouth container. The gel  was  filled  in  the  wide  mouth  
container in such way that it should  sufficiently  allow  to  
dip  the  spindle of the Viscometer. Samples of the gels were 
allowed to settle over 30 min at the constant temperature 
(25 ±/10C) before the measurements.  
In-vitro drug release studies using the prehydrated 
cellophane membrane  
The cellophane membrane approximately 25 cm x 2cm was 
taken and washed in the running water. It was then soaked 
in distilled water for 24 hours, before used for diffusion 
studies to remove glycerin present on it and was mounted 
on the diffusion cell for further studies. The drug release 
studies were carried out using modified franz diffusion cell. 
The cellophane membrane was mounted on the Franz 
diffusion cell. Formulation was applied through donor 
compartment on the dialysis membrane. Reservoir 
compartment was filled with 25 ml phosphate buffer of pH 
7.4 The study was carried out at 37 ± 1°C and at a speed of 
100 rpm for 8  h. Samples were withdrawn from reservoir 
compartment at 1 h interval and absorbance was measured 
spectrophotometrically at 242.0nm.  Each time the reservoir 
compartment was replenished with the same quantity of 7.4 
pH phosphate buffer10,11 . 
Release kinetics 
In order to elucidate mode and mechanism of drug release, 
the invitro data was transformed and interpreted at 
graphical interface constructed using various kinetic models. 
The zero order release Eq. (1) describes the drug dissolution 
of several types of modified release pharmaceutical dosage 
forms, as in the case of transdermal systems, matrix tablets 
with low soluble drugs, coated forms, osmotic systems etc., 
where the drug release is independent of concentration.  
Qt = Qo + Kot (1) 
Where, Qt is the amount of drug released in time t, Qo is the 
initial amount of the drug in the solution and Ko is the zero 
order release constant  
The first order Eq. (2) describes the release from the system 
where release is concentration dependent e.g. 
pharmaceutical dosage forms containing water soluble 
drugs in porous matrices.  
log Qt = log Qo + K1 t /2.303 (2) 
Where Qt is the amount of drug released in time t, Q is the 
initial amount of drug in the solution and K1 is the first 
order release constant.  
Higuchi described the release of drug from insoluble matrix 
as a square root of time as given in Eq. (3)  
Qt = KH √t (3) 
Where, Qt is the amount of drug released in time t, KH is 
Higuchi’s dissolution constant 12.  
The following plots were made: cumulative % drug release 
vs. time (zero order kinetic models); log cumulative of % 
drug remaining vs. time (first order kinetic model); 
cumulative % drug release vs. square root of time (Higuchi 
model). 
Stability studies 
Stability studies were carried out with optimized 
formulation which was stored for a period of 45 days at 
4±1°C, RT and 40±1°C. The particle size of formulation was 
determined by optical microscopy using a calibrated ocular 
micrometer.  
RESULTS AND DISCUSSIONS 
Acyclovir was found to be white off crystalline powder in 
appearance, odourless and tasteless. The melting point of 
ACV (pure drug) was found to be 256-258oC; it matches with 
the standard (256.5 °C). ACV was freely soluble in ethanol, 
methanol, 0.1 N HCl, slightly soluble in 0.1 N NaOH, distilled 
water and soluble in chloroform, phosphate buffer pH 7.4. 
The absorption maxima of ACV were determined by running 
the spectrum of drug solution in double beam ultraviolet 
spectrophotometer (Labindia UV 3000+) using 
concentration range of 5-25μg/ml ACV in 7.4 phosphate 
buffers Fig 1. Vesicle size and zeta potential of the 
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ethosomes were measured by photon correlation 
spectroscopy using a Malvern Zetasizer and entrapment 
efficiency was determined by measuring the concentration 
of unentrapped free drug in aqueous medium by UV 
spectrophotometer the results shown in Table 3. Zeta 
potential of optimized ethosomes formulation (AEF5) was 
found -20.5 mV Table 4. Results of evaluation of ethosomal 
gel formulation (AEG1- AEG3) of optimized formulation 
(AEF5) were incorporated into three different carbapol gel 
concentration 0.5, 1 and 1.5 % w/w respectively. 
Formulation AEG2was found to be good Table 5. Results of 
In-vitro drug release from optimized formulation (AEG2) are 
given in table 6  was found 82.23 after 8 hrs. The in vitro 
drug release data of the formulation was subjected to 
goodness of fit test by linear regression analysis according to 
zero order, first order kinetic equation and Korsmeyer’s -
pappas models in order to determine the mechanism of drug 
release. When the regression coefficient values of were 
compared, it was observed that ‘r’ values of formulation was 
maximum i.e 0.989 hence indicating drug release from 
formulations was found to follow zero order model of drug 
release kinetics. Table 7 and Fig 2, 3. 
 
Figure 1 Wavelength maxima of ACV in phosphate buffer 
pH 7.4 
Table 3 Result for vesicle size and entrapment efficiency 
of drug loaded ethosomes 
Formulation 
Code  
Vesicle size  
(mm) 
% Entrapment 
efficiency 
AEF1 458.56±0.23 69.98±0.25 
AEF2 426.65±0.45 65.58±0.74 
AEF3 433.22±0.52 63.32±0.65 
AEF4 415.65±0.36 70.12±0.58 
AEF5 331.69±0.65 79.98±0.41 
AEF6 485.45±0.58 68.12±0.25 
 
Table 4 Characterization of optimized formulation of ethosomes 
Formulation Code Vesicle size (nm) Entrapment Efficiency Zeta potential (mV) 
AEF5 331.6 79.98±0.41 -20.5 
 
Table 5 Results of evaluation of gel formulation 
Code 
Homogeneity and 
texture 
 
pH 
Spreadability 
(gm.cm/sec.) 
Viscosity 
(cps) 
% Assay 
AEG1 Particle present 6.80±0.05 12.56±0.45 2225±10 98.56±0.45 
AEG2 Smooth 7.12±0.03 11.23±0.32 2365±15 99.12±0.23 
AEG3 Smooth 6.95±0.06 10.25±0.25 2456±23 98.45±0.56 
 
Table 6 In Vitro drug release data for AEG2 
Time 
(H) 
Square 
Root of 
Time 
Log Time 
Cumulative* 
Percentage Drug 
Release 
Log Cumulative 
Percentage 
Drug Release 
Cumulative 
Percent Drug 
Remaining 
Log cumulative 
Percent Drug 
Remaining 
0.5 0.707 -0.301 24.56 1.390 75.44 1.878 
1 1 0 30.25 1.481 69.75 1.844 
2 1.414 0.301 42.23 1.626 57.77 1.762 
4 2 0.602 55.65 1.745 44.35 1.647 
6 2.449 0.778 68.89 1.838 31.11 1.493 
8 2.828 0.903 82.23 1.915 17.77 1.250 
* Average of three determinations 
Table 7 Regression analysis data of ethosomal gel formulation 
Formulation Zero order First order 
AEG2 R² = 0.989 R² = 0.982 
 
 
Figure 2 Cumulative percent drug released vs time 
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Figure 3 Log Cumulative percent drug remaining vs time 
CONCLUSION 
Ethosomes of ACV were prepared successfully by using 
different concentrations of phospholipids and ethanol as 
well as the incorporation of the ethosomes into carbopol 934 
base gel to obtain ethosomal gel formulations. The prepared 
formulations were characterized for various properties. The 
compositions of ethosomes and gels were manipulated to 
investigate their effects on the characteristics of final 
formulations. It can serve as a useful vehicle for the delivery 
of ACV through the affected part of the skin for extended 
period of time. This study also revealed that ethosomal gel 
(AEG2) resides at targeted site for a relatively longer period 
of time with a zero order release profile. It signifies the 
improved patient compliance. 
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